Recent developments in the treatment of type 2 diabetes mellitus.
The last couple of decades have seen a great improvement in our understanding of risk factors in diabetes. In particular, a number of studies have demonstrated the major harmful role of hypertension in combination with diabetes. In a parallel development, pharmacological developments have greatly increased our ability to control both blood pressure and glycaemic exposure. This review focuses on hypertension as a risk factor and of the role of emerging therapies, in the light of their effects beyond the direct lowering of blood pressure. Agents that interfere with the renin-angiotensin system, particularly angiotensin-receptor blockers, may have particular benefits on end-organs in diabetic patients.
Ruilope
Luis M
LM
Hospital 12 de Octubre, Servicio de Nefrologia, Madrid, Spain. lru00001@teleline.es
D000959:Antihypertensive Agents / Q000627:therapeutic use; D001786:Blood Glucose; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000188:drug therapy; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D040242:Risk Reduction Behavior
D000959:Antihypertensive Agents; D001786:Blood Glucose; D007004:Hypoglycemic Agents